Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

Trial Profile

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MIV-818 (Primary)
  • Indications Cholangiocarcinoma; Liver cancer; Liver metastases
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Medivir AB
  • Most Recent Events

    • 18 Nov 2019 According to a Medivir AB media release, efficacy data from the complete phase Ia study will be presented next year at a scientific conference.
    • 18 Nov 2019 According to a Medivir AB media release, company has completed the recruitment of the ninth and final patient for the phase Ia part of the study. Based on data from phase Ia, the initial dose of MIV-818 for the phase Ib study has been determined at 200 mg / week. The dosage is given as 40 mg / day for five days.
    • 28 Aug 2019 According to a Medivir AB media release, based on the positive results from the first six patients, the company decided to to proceed with the phase Ib part which is expected to start in Q4 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top